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ABSTRACT
MALLORY MAIER: Synthesis of Difluoromethyl and Monofluoromethyl Ketones for
Biological Evaluation at the GABAB Receptor
(Under the direction of David A. Colby)
The central nervous system communicates using neurotransmitters. Most are
excitatory neurotransmitters, such as acetylcholine, dopamine, and serotonin, but 𝛾aminobutyric acid (GABA) is the primary inhibitory neurotransmitter. There are two
main types of GABA receptors. The GABAa receptors are ion channels and are targeted
by many drugs. However, there is a specific interest in developing compounds to interact
with GABAB receptors due to potential use as addiction treatments. There is currently
only one FDA approved drug on the market, a muscle relaxer called baclofen, that
selectively binds to GABAB receptors. The goal of this project was to synthesize
fluorinated compounds to be evaluated at the GABAB receptor. The incorporation of
fluorine into organic molecules is becoming increasingly important in the pharmaceutical
industry. Specifically, fluorinated ketones are an important functional group in medicinal
chemistry, but existing methods to synthesize this functional group are low yielding. A
new method has been developed to access difluoromethyl ketones through the release of
trifluoracetate, and some of these molecules have been shown to serve as agonists of the
GABAB receptor. My project is the modification of this method to generate
monofluoromethyl ketones to be submitted for biological evaluation at the GABA B
receptor.
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1. Introduction
1.1

Communication in the Central Nervous System
Neurons, the functional cells of the central nervous system (CNS), communicate
through impulses that release neurotransmitters resulting in either the excitation or
inhibition of the post-synaptic cell. Neurons consist of three primary parts: the cell
body, dendrites, and the axon. These structures form synapses with other neurons or
receptors during neurotransmission. Dendrites are short arms on the nerve cell that
conduct information toward the cell body. The axon extends from the cell body, and
the terminal end forms a synapse with other neurons or receptor cells. The axon
conducts nerve impulses from the cell body, called action potentials, to the terminal
end.
When the action potential reaches the terminus of the axon, the neuron
communicates with the postsynaptic cell through either an electrical or a chemical
signal. Chemical synapses are most commonly found in the CNS. When the action
potential reaches the terminal of the axon, it signals the release of chemical
messengers called neurotransmitters. Neurotransmitters are released from the axon
into the synapse, and they bind to their receptors on the membrane of the postsynaptic
cell.
Neurotransmitters are synthesized and stored in the axon terminal in synaptic
vesicles. When the action potential reaches the terminal, it causes the
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vesicles to move to the membrane and release the neurotransmitters into the
synapse. There are various physiological processes in place to remove the
neurotransmitters from the synapse to maintain precise control of neural transmission.
These processes include reuptake of the neurotransmitter by the axon, metabolism of
the neurotransmitter, or diffusion into intercellular fluid resulting in decreased
concentration.
There are two types of chemical synapses: excitatory and inhibitory. In an
excitatory synapse, when the neurotransmitter binds to its receptor on the
postsynaptic membrane, it results in the depolarization of the postsynaptic membrane
resulting in the continuation of an action potential. The binding of neurotransmitters
in an inhibitory synapse reduces the postsynaptic cell’s ability to generate an action
potential. This effect is generally accomplished by hyperpolarizing the postsynaptic
membrane, making it more permeable to potassium and/or chloride ions, and less
likely to depolarize.
1.2

GABA
Most neurotransmitters in the CNS are excitatory. The primary inhibitory
neurotransmitter in the CNS is -aminobutyric acid (GABA). Its major roles are to
regulate the excitation of neurons as well as regulate the release of other
neurotransmitters.2 There are two major types of GABA receptors that determine the
actions of GABA: GABAA and GABAB. GABA receptors are a long-standing target
in the pharmaceutical industry.
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1.2.1

GABAA Receptors
GABAA receptors are pentamers consisting of two identical 
subunits, two identical  subunits and one “other” subunit assembled
around a central pore. Sixteen subunits have been identified that make up
GABAA receptors. The receptors are ligand-gated chloride-ion channels
that suppress excitation in neurons.3 When GABA binds to the GABAA
receptor, it increases the cells permeability to chloride which reduces the
cells ability to generate an action potential.4
GABAA receptors are the most therapeutically targeted GABA
receptor. There are three major classes of pharmaceuticals that target
GABAA receptors: barbituates, benzodiapepines, and nonbenzodiazepines.5 These drugs treat various disease states including
anxiety, insomnia, seizures and muscle spasms.

1.2.2

GABAB Receptors
GABAB receptors are heterodimeric, G-protein coupled receptors.
The dimer is made up of GABAB1, which contains the GABA binding
regions, and GABAB2, which activates the G-protein.6 These receptors
inhibit the release of several neurotransmitters including acetylcholine,
serotonin, dopamine, and noradrenaline through G-protein-dependent
inhibition of voltage-gated calcium channels.7 They can also reduce
neuronal excitation through activation of G-protein regulated potassium
channels, and regulate intracellular signaling through inhibition of
adenylyl cyclase ativity.7,8
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GABAB receptors can be linked to the pathophysiology of many
CNS diseases and disorders such as anxiety, depression, autism spectrum
disorders, stroke, drug addiction, Huntington’s disease, Parkinson’s
disease and Alzheimer’s disease. They can also be linked to muscle
spasticity disorders, pain and gastroesophageal reflux disease (GERD).3
Unlike GABAA receptors, there are few pharmaceuticals that target
GABAB receptors. Implications of targeting the GABAB receptor include
treatment of anxiety, mood disorders, and addiction to alcohol, cocaine,
heroin, and nicotine. There remains a great deal of potential in the
pharmaceutical industry to create drugs that target GABA B receptors.
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1.3

Baclofen and Other GABAB Agonists
Currently, baclofen, a muscle relaxant, is the only FDA approved drug that
targets the GABAB receptor.3 The structure of GABA is imbedded in the structure
of baclofen (Figure 1). Baclofen is used primarily to treat muscle spasms in
patients with multiple sclerosis or spinal cord injuries. However, baclofen has
been shown to be effective in off-label treatment and possible treatment of various
ailments caused in part by pathogenesis of the GABAB receptor pathway, such as
GERD9, nicotine addiction, and post-traumatic stress disorder10. Despite its
exclusivity as the only FDA approved GABAB agonist drug, balcofen is far from
ideal. Baclofen has low penetration into the brain, a narrow therapeutic window,
short duration of action and a rapid tolerance.11,12 The development of GABAB
agonists that could overcome these barriers would be a substantial improvement
over baclofen.
Previous research has shown that making even subtle changes to the
structure of baclofen can produce antagonists, eliminate activity at the GABA B
receptor altogether, or even cause the compound to interact with other GABA
receptors.3 Baclofen derivatives with structural modifications at the 3-position are
GABAB agonists.2 For example, 3-aminopropyl phosphinic acid has been
demonstrated to be a potential inhibitor of GERD, muscle relaxant and treatment
for addiction.13
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Figure 1 Structures of GABA and baclofen
1.4

Fluorine and Medicinal Chemistry
Incorporation of fluorine into organic compounds has become increasingly
important in pharmaceuticals. Over the past several decades, 5–15% of the total
number of new drugs launched worldwide were fluorinated.14 Fluorine is the most
electronegative element which gives it certain inherent properties. Incorporating
fluorine into drug molecules affects the pKa of the drug and can influence certain
characteristics such as solubility, permeability and protein binding of the drug.15
These characteristics, in turn, affect the absorption, distribution, metabolism and
elimination of the drug. There are many examples of molecules where fluorine
effectively replaced hydrogen or oxygen and maintained comparable activities at
the site of action for the drug.14
Fluorine increases the permeability of a drug, which means it is more able
to pass through a cell membrane. As the lipophilicity of a drug increases,
likewise, the permeability of the drug increases.15 The lipophilicity of drugs is
measured and reported as log P values, with a lower log P value being associated
with higher lipophilicity.15 Mono- and di-fluorination of molecules have been
shown to result in significant reductions of log P values for drugs.15 By increasing
permeability of a drug, it simultaneously increases the bioavailability of the drug.
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This improvement is of great importance when developing new drugs, especially
those that must cross the blood-brain barrier.
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2. Results and Discussion
2.1 Synthesis of Difluoromethyl Ketones
While there is not much data on the structure of the GABAB receptor, it is known
that two key active-site residues include Ser246 and Asp471. These residues have
critical interactions with baclofen and GABA.16 The carboxylate of baclofen interacts
with the serine residue of the GABAB receptor, which led researchers to believe that
α-fluorinated ketones might interact similarly due to their ability to form hemiketals
with serine residues in an active site and serve as surrogates for carboxylic acids and
phosphinic acids.2
Difluoromethyl ketones were synthesized because of the ketone’s ability to revert
to a gem diol in water (Figure 2) which increases its solubility and affords a
tetrahedral shape, which can enable activity as a transition state mimic. 1 The
difluoromethyl-starting material was synthesized from (Z)-4,4,4-trifluoro-3-hydroxy1-(naphthalen-2-yl)but-2-en-1-one and selectfluor under anhydrous conditions (see
experimental details). A novel method has been discovered that was used to assemble
the difluoromethyl ketones by aldol reactions with difluoroenolates following the
release of trifluoroacetate in the presence of triethylamine (Figure 3).17 Once
triflouroacetate is released, the aldol reaction is rapid, resulting in the enolate
attacking the electrophilic carbon of the aldehyde (Figure 3). Following an aqueous
workup, the desired difluoromethyl ketone is obtained.

Figure 2 Ketone reverts to gem diol in presence of water
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Figure 3 Difluoromethyl ketone from trifluoroacetate release and aldol addition
Unlike many other routes for fluorochemical synthesis, this approach yields
difluoromethyl ketones in three synthetic steps with a high yield. The method is also
versatile and can be used with many different ketones. 2 Using this approach, four
difluoromethyl ketones were synthesized to reproduce reported procedures in the
literature, as well as to learn the methods and techniques of synthesizing these
compounds (Figure 4). Each compound was obtained in good yield and purified by
silica flash chromatography. The reaction with cyclohexylcarbaldehyde required a
lower temperature to achieve an acceptable yield. Each of these compounds were
submitted for biological evaluation.
2.2 Synthesis of Monofluoromethyl Ketones
It is reported in the literature that difluoromethyl ketones show activity at the
GABAB receptor.2 The goal of this project was to find out what, if any, activity
monofluoromethyl ketones have at the GABAB receptor. Another goal was to
compare how the activity of monofluoromethyl ketones compare to the reported
activity of difluoromethyl ketones.
The general synthesis of monofluoromethyl ketones is very similar to that of
difluoromethyl ketones, with one key difference. The starting material was
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Figure 4 Synthesis of difluoromethyl ketones 14
synthesized from reacting (Z)-4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en1-one with selectfluor in the presence of water, which lead to monofluorination of the
compound (Figure 5). The mechanisms and reaction conditions involving
trifluoroacetate release and the aldol additions remained the same. The same four
aldehydes used in the difluoromethyl ketones syntheses were used in the
monofluoromethyl ketone syntheses (Figure 6).

Figure 5 Monofluorination of starting material
2.3 Identification and Purification of Difluoromethyl Ketones and Monofluoromethyl
Ketones
Two primary techniques were used to identify compounds in the synthesis of both
the difluoromethyl ketones and the monofluoromethyl ketones: thin layer
chromatography (TLC) and nuclear magnetic resonance spectroscopy (NMR). TLC
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Figure 6 Synthesis of monofluoromethyl ketones 58
was used to monitor the progress of the reactions. The difluoromethyl ketones were
synthesized at a rapid rate and leaving behind very little starting material. The
monofluoromethyl ketones, synthesized under analogous conditions, resulted in much
lower yields compared to their difluoro-counterparts. TLC was used to monitor the
progress of the reactions. It was later discovered that the loss of product occurred
during the transfer of the products from one container to another.
TLC was also used to optimize solvent systems for the purification of the
products using flash column chromatography, as well as to assist in collection of the
products. The solvents used to purify the difluoromethyl ketones, as reported in the
literature, resulted in the successful separation and purification of compounds at
relatively high yields. When trying to duplicate purification procedures for the
monofluoromethyl ketones, separation was not ideal. The solvent systems had to be
optimized for each monofluormethyl compound based on the polarity of the
compound and the starting materials (see experimental details).
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Once the compounds had been purified using flash column chromatography,
NMR data was analyzed to confirm the purity of the compound. Proton NMR was
used to determine if any non-fluorinated starting materials, or other impurities,
remained with the product. Impurities contaminating the desired compounds could
have lead to inaccurate results in biological testing of the activity of the compound at
the GABAB receptor. Fluorine NMR was used to verify that the starting material was
not present, and that the correct number of fluorines were present on the desired
compound. This data was especially important for the monofluoromethyl ketones to
make sure that the difluoromethyl ketones were not present, because difluoromethyl
ketones could alter the results of biological testing. Since it is already known that
difluoromethyl ketones are active at the GABAB receptor, a mixture of
difluoromethyl and monoflouomethyl ketones could lead to false biological activity
results.
2.4 Biological Evaluation at the GABAB Receptor
Biological evaluation of GABA, baclofen, and difluoromethyl ketones was
performed to measure selectivity and potency at the GABAA and GABAB receptors,
and the values were reported (Table 1).2 GABAB agonist activity was measured using
a cell line expressing subunits of the human GABAB receptor that when activated,
inhibits the production of cAMP.2 In the assay, forskolin, an activator of adenylyl
cyclase, was used to stimulate cAMP production. Inhibition of forskolin-stimulated
accumulation of cAMP was measured and reported.2
Baclofen and GABA were used as positive controls in the assay, and the results
were comparable to other reported EC50 values in the literature.2 The lower the EC50
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value, the more potent the compound is at the receptor. Based on the values reported
in Table 1, the difluoromethyl ketones synthesized show significant activity and
selectivity at the GABAB receptor. Although compound 9 was not synthesized in this
project, it shows the greatest potency at the GABAB receptor.
The goal of this project was to determine how the biologic activity of
monofluoromethyl ketones compares to that of baclofen, GABA and the
difluoromethyl ketones. Compound 10 (Table 1), was synthesized and tested by
another member of David Colby’s lab at the University of Mississippi, and it is
reported that it showed a greater potency at the GABAB receptor than its difluoroanalog. These data drive the need to determine whether all monofluoromethyl ketones
would show greater potency at the GABAB receptor over difluoromethyl ketones.
Compounds 5–8 have been submitted for biological evaluation, but no data has been
received. It is not known why the monofluorinated compound 10 exhibits greater
activity than the difluorinated compound 9.
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Table 1 Biologic activity at the GABAB receptor

Compound
GABA
Baclofen

GABAB EC50 (M)a

GABAA EC50 (M)a

0.53  0.33
1.7  0.10 b

>100 b
2.30  0.59 b

61.8  3.01 b

>100 b

53.5  1.76 b

>100 b

99.3  3.78 b

>100 b

66.9  1.19 b

>100 b

24.9  1.30 b

>100 b

12.2

nd

nd

nd

nd

nd

nd

nd

nd

nd

1

2

3

4

9

10

5

6

7

8
a

Values are given with standard error.
Source: Han, C.; Salyer, A. E.; Kim, E. H.; Jiang, X.; Jarrad, R. E.; Powers, M. S.; Kirchhoff, A.
M.; Salvador, T. K.; Chester, J. A.; Hockerman, G. H.; Colby, D. A. Evaluation of
Difluoromethyl ketones as Agonists of the 𝛾-Aminobutyric Acid Type B Receeptor. Med. Chem.
2013, 56, 2456–2465
b

14

3. Conclusion
In summary, eight fluorinated compounds were synthesized to be evaluated at the
GABA receptors. Four difluoromethyl ketones were synthesized using a novel method
involving the release of trifluoroacetate to extend the scope of the published procedure.
The compounds were purified via flash column chromatography and the purity of the
compounds was evaluated using 1H NMR and 19F NMR. Additionally, four
monofluoromethyl ketones were synthesized using similar techniques to be biologically
evaluated at the GABAB receptor. The goal of the project was to determine if
monofluoromethyl ketones have a greater potency than difluoromethyl ketones at the
GABAB receptor. Samples of monofluormethyl ketones were sent for biological testing,
but no results have been received at this time.
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4. Experimental Details

2,2,4,4,4-Pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one. A mixture of
(Z)-4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one (0.500 g, 1.88 mmol)
and acetonitrile (12.5 mL) was treated with selectfluor (1.66 g, 4.70 mmol) at rt under
argon. After 20 h, the reaction was diluted with ethyl acetate (125 mL) and filtered
through Celite. The residue was concentrated in vacuo, dissolved in dichloromethane (50
mL) and washed with water (50 mL). The aqueous layer was extracted with
dichloromethane (50 mL). The organics were dried over Na2SO4 and concentrated under
reduced pressure. The solid product was afforded in 92% yield: 1H NMR (500 MHz,
CDCl3) δ 8.74 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.7
Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.70 (t, J = 7.0 Hz, 1H), 7.61 (t, J = 7.1 Hz, 1H), 4.74
(s, 2H).

2,2-Difluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)propan-1-one, 1. A
mixture of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg,
0.2 mmol), p-anisaldehyde (38 L, 0.31 mmol), and LiBr (41 mg, 0.47 mmol) in THF (1
mL) was treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction was
stirred at rt for 10 min, and was quenched with saturated aqueous NH 4Cl (3 mL). The
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (3.5:1.5
hexanes/ethyl acetate) afforded the product as a solid in 77% yield: 1H NMR (500 MHz,
CDCl3) δ 8.62 (s, 1H), 8.05 (d, J = 9.1 Hz, 1H), 7.97 – 7.84 (m, 2H), 7.65 (t, J = 7.0 Hz,
1H), 7.57 (t, J = 7.4 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 5.39 (dd,
16

J = 18.0, 5.9 Hz, 1H), 3.81 (s, 3H), 2.99 (s, 1H).

3-Cyclohexyl-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)propan-1-one, 2. A mixture
of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2
mmol), cyclohexanecarbaldehyde (38 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in
THF (1 mL) was treated with triethylamine (86 L, 0.62 mmol) dropwise. The reaction
was stirred at 78C for 30 min, and was quenched with saturated aqueous NH 4Cl (3
mL). The mixture was extracted with ethyl acetate (3 mL  5). The organics were dried
over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (9:1
hexanes/ethyl acetate) afforded the product as a solid in 84% yield: 1H NMR (500 MHz,
CDCl3) δ 8.70 (s, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.90 (dd, J =
12.2, 8.5 Hz, 3H), 7.65 (dt, J = 8.2, 1.2 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 4.13 (dq, J =
19.6, 6.1 Hz, 1H), 2.43 (d, J = 6.7 Hz, 1H), 2.12–1.53 (m, 6H), 1.47–1.16 (m, 5H).

(4E,6E)-2,2-Difluoro-3-hydroxy-1-(naphthalen-2-yl)octa-4,6-dien-1-one, 3. A mixture
of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2
mmol), (2E,4E)-hexa-2,4-dienal (34 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in
THF (1 mL) was treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction
was stirred at rt for 10 min, and was quenched with saturated aqueous NH 4Cl (3 mL). The
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (9:1
hexanes/ethyl acetate) afforded the product as a solid in 55% yield: 1H NMR (500 MHz,
CDCl3) δ 8.71 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.89 (dd, J =
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11.0, 8.6 Hz, 2H), 7.65 (t, J = 7.1 Hz, 1H), 7.57 (t, J = 7.9 Hz, 1H), 6.45 (dd, J = 15.3,
10.5 Hz, 1H), 6.21 – 5.97 (m, 1H), 5.90 – 5.76 (m, 1H), 5.72 (dd, J = 15.4, 6.9 Hz, 1H),
4.85 (dt, J = 14.7, 6.9 Hz, 1H), 2.74 (s, 1H), 1.78 (d, J = 6.5 Hz, 3H).

(E)-2,2-Difluoro-3-hydroxy-1-(naphthalen-2-yl)oct-4-en-1-one, 4. A mixture of
2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.3 mmol),
(E)-hex-2-enal (37 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in THF (1 mL) was
treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction was stirred at rt for
10 min, and was quenched with saturated aqueous NH 4Cl (3 mL). The mixture was
extracted with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and
concentrated under reduced pressure. SiO2 flash chromatography (9:1 hexanes/ethyl
acetate) afforded the product as a solid in 45% yield: 1H NMR (500 MHz, CDCl3) δ 8.71
(s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.90 (dd, J = 11.9, 8.5 Hz, 2H),
7.65 (t, J = 7.5 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 5.96 (dt, J = 14.2, 6.7 Hz, 1H), 5.66 (dd,
J = 15.5, 6.9 Hz, 1H), 4.78 (dq, J = 13.0, 6.5 Hz, 1H), 2.61 (d, J = 5.6 Hz, 1H), 2.10 (q, J
= 7.0 Hz, 2H), 1.43 (q, J = 7.3 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H).

2,4,4,4-Tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one. A mixture of (Z)4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one (0.500 g, 1.88 mmol), water
(6 mL) and acetonitrile (6 mL) was treated with selectfluor (0.665 g, 1.88 mmol) at rt
under air. After 18 h, the residue was washed with water (50 mL). Saturated aqueous
NaCl (10 mL) was added to the mixture and the product was extracted with
dichloromethane (10 mL  5). The combined organics were dried over Na2SO4 and
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concentrated under reduced pressure. The solid product was afforded in 88% yield: 1H
NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 8.02 (dd, J = 7.7, 4.5 Hz, 2H), 7.92 (dd, J =
14.2, 8.4 Hz, 2H), 7.68 (t, J = 8.1 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 5.87 (d, J = 47.8 Hz,
1H), 4.90 (s, 1H), 4.55 (s, 1H); 19F NMR (376 MHz, CDCl3) δ –83.9 (d, J = 11.5 Hz, 3F),
–194.6 (dq, J = 47.7, 11.2 Hz, 1F).

2-Fluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)propan-1-one, 5. A
mixture of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2
mmol), cyclohexanecarbaldehyde (40 L, 0.33 mmol), and LiBr (72 mg, 0.82 mmol) in
THF (1 mL) was treated with triethylamine (27 L, 0.20 mmol) dropwise. The reaction
was stirred at rt for 30 min, and was quenched with saturated aqueous NH 4Cl (3 mL). The
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (3.5:1.5
hexanes/ethyl acetate) afforded the product as an inseparable mixture of diastereomers
(dr = 1.78:1) in 23% yield: 1H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 15.2 Hz, 1H), 7.94
(dd, J = 14.1, 9.2 Hz, 2H), 7.91–7.85 (m, 2H), 7.63 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.4
Hz, 1H), 7.38 (dd, J = 8.6, 3.9 Hz, 2H), 6.87 (dd, J = 12.4, 8.7 Hz, 2H), 5.85–5.58 (m,
1H), 5.31 (d, J = 22.5 Hz, 1H), 3.76 (d, J = 14.0 Hz, 3H), 2.98 (s, 1H); 19F NMR (376
MHz, CDCl3) δ –188.9– –189.9* (m, 1F), –195.9 (dd, J = 48.4, 21.3 Hz, 1F). *Denotes
minor diastereomer.

3-Cyclohexyl-2-fluoro-3-hydroxy-1-(naphthalen-2-yl)propan-1-one, 6. A mixture of
2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol), p-
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anisaldehyde (40 L, 0.3 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL) was treated
with triethylamine (92 L, 0.66 mmol) dropwise. The reaction was stirred at rt for 10
min, and was quenched with saturated aqueous NH4Cl (3 mL). The mixture was extracted
with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and concentrated
under reduced pressure. SiO2 flash chromatography (4:1 dichloromethane/hexanes)
afforded the product as a solid in 57% yield: 1H NMR (500 MHz, CDCl3) δ 8.58 (s, 1H),
8.03 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.90 (dd, J = 11.6, 8.5 Hz, 2H), 7.63 (t,
J = 6.9 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 5.60 (dd, J = 47.7, 7.0 Hz, 1H), 4.06 (s, 1H),
2.46 (s, 1H), 1.97–1.54 (m, 6H), 1.46–1.11 (m, 5H); 19F NMR (376 MHz, CDCl3) δ –
190.7 (dd, J = 47.8, 9.8 Hz, 1F).

(4E,6E)-2-Fluoro-3-hydroxy-1-(naphthalen-2-yl)octa-4,6-dien-1-one, 7. A mixture of
2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol),
(2E,4E)-hexa-2,4-dienal (38 L, 0.33 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL)
was treated with triethylamine (23 L, 0.16 mmol) dropwise. The reaction was stirred at
rt for 30 min, and was quenched with saturated aqueous NH 4Cl (3 mL). The mixture was
extracted with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and
concentrated under reduced pressure. SiO2 flash chromatography (9:1 hexanes/ethyl
acetate) afforded the product as an inseparable mixture of diastereomers (dr = 15:1) in
40% yield: 1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.99 (t, J = 8.8 Hz, 2H), 7.95 –
7.84 (m, 2H), 7.63 (t, J = 8.0, 6.9 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 6.36 (dd, J = 15.5,
10.3 Hz, 1H), 6.03 (t, J = 12.9 Hz, 1H), 5.86–5.47 (m, 3H), 4.78 (d, J = 21.1 Hz, 1H),
2.36 (s, 1H), 1.75 (d, J = 6.6 Hz, 3H); 19F NMR (376 MHz, CDCl3) δ –194.2* (dd, J =
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48.6, 15.0 Hz, 1F), –198.5 (dd, J = 48.3, 21.7 Hz, 1F). *Denotes minor diastereomer.

(E)-2-Fluoro-3-hydroxy-1-(naphthalen-2-yl)oct-4-en-1-one, 8. A mixture of 2,4,4,4tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol), (E)-hex-2enal (38 L, 0.33 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL) was treated with
triethylamine (23 L, 0.16 mmol) dropwise. The reaction was stirred at rt for 30 min, and
was quenched with saturated aqueous NH4Cl (3 mL). The mixture was extracted with
ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and concentrated under
reduced pressure. SiO2 flash chromatography (4:1:0.5 dichloromethane/hexanes/ethyl
acetate) afforded the product as an inseparable mixture of diastereomers (dr = 1.6:1) in
83% yield: 1H NMR (500 MHz, CDCl3) δ 8.54 (d, J = 5.6 Hz, 1H), 7.99 (t, J = 8.4 Hz,
2H), 7.95–7.85 (m, 2H), 7.64 (t, J = 7.5 Hz, 1H), 7.60–7.54 (m, 1H), 5.94–5.49 (m, 3H),
4.71 (dd, J = 16.9, 6.7 Hz, 1H), 2.46 (s, 1H), 2.00 (d, J = 6.8 Hz, 2H), 1.40–1.30 (m, 2H),
0.84 (td, J = 7.4, 3.6 Hz, 3H); 19F NMR (376 MHz, CDCl3) δ –195.5 (dd, J = 48.4, 16.3
Hz, 1F), –198.4* (dd, J = 48.5, 21.0 Hz, 1F). *Denotes minor diastereomer.
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